HeraMED Limited
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It also provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a remote fetal heart rate monitoring solution. The company has a collaboration agreement with Mayo Clinic for the … Read more
HeraMED Limited (1I4) - Net Assets
Latest net assets as of December 2024: €2.77 Million EUR
Based on the latest financial reports, HeraMED Limited (1I4) has net assets worth €2.77 Million EUR as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.48 Million) and total liabilities (€1.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.77 Million |
| % of Total Assets | 61.8% |
| Annual Growth Rate | -12.44% |
| 5-Year Change | 6.81% |
| 10-Year Change | N/A |
| Growth Volatility | 1428.23 |
HeraMED Limited - Net Assets Trend (2018–2024)
This chart illustrates how HeraMED Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HeraMED Limited (2018–2024)
The table below shows the annual net assets of HeraMED Limited from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €2.77 Million | +3502.08% |
| 2023-12-31 | €76.93K | -98.17% |
| 2022-12-31 | €4.21 Million | +4068.84% |
| 2021-12-31 | €-105.98K | -104.09% |
| 2020-12-31 | €2.59 Million | -23.88% |
| 2019-12-31 | €3.41 Million | -44.57% |
| 2018-12-31 | €6.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to HeraMED Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3916829800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €49.10 Million | 1771.90% |
| Total Equity | €2.77 Million | 100.00% |
HeraMED Limited Competitors by Market Cap
The table below lists competitors of HeraMED Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PharmaSGP Holding SE
F:PSG
|
$17.11 Million |
|
Kainos Medicine Inc
KQ:284620
|
$17.12 Million |
|
Southern Energy Corp
V:SOU
|
$17.12 Million |
|
Iz Hayvancilik Tarim ve Gida Sanayi Ticaret AS
IS:IZINV
|
$17.12 Million |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
$17.10 Million |
|
TREJHARA SOLUTIONS LIMITED
NSE:TREJHARA
|
$17.09 Million |
|
Ecocab Co. Ltd
KQ:128540
|
$17.09 Million |
|
Rigolleau SA
BA:RIGO
|
$17.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HeraMED Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 685,011 to 2,771,109, a change of 2,086,098 (304.5%).
- Net loss of 5,490,578 reduced equity.
- New share issuances of 7,082,833 increased equity.
- Other factors increased equity by 493,843.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-5.49 Million | -198.14% |
| Share Issuances | €7.08 Million | +255.6% |
| Other Changes | €493.84K | +17.82% |
| Total Change | €- | 304.53% |
Book Value vs Market Value Analysis
This analysis compares HeraMED Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.33x to 7.43x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €0.07 | €0.02 | x |
| 2019-12-31 | €0.03 | €0.02 | x |
| 2020-12-31 | €0.02 | €0.02 | x |
| 2021-12-31 | €0.00 | €0.02 | x |
| 2022-12-31 | €0.02 | €0.02 | x |
| 2023-12-31 | €0.00 | €0.02 | x |
| 2024-12-31 | €0.00 | €0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HeraMED Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -198.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1507.04%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.62x
- Recent ROE (-198.14%) is above the historical average (-245.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -86.78% | -4880.82% | 0.01x | 1.27x | €-5.95 Million |
| 2019 | -131.03% | -2152.08% | 0.04x | 1.51x | €-4.81 Million |
| 2020 | -168.10% | -8500.28% | 0.01x | 1.60x | €-4.62 Million |
| 2021 | 0.00% | -6588.20% | 0.02x | 0.00x | €-5.70 Million |
| 2022 | -170.56% | -2229.48% | 0.05x | 1.45x | €-7.59 Million |
| 2023 | -964.81% | -1117.60% | 0.21x | 4.08x | €-6.68 Million |
| 2024 | -198.14% | -1507.04% | 0.08x | 1.62x | €-5.77 Million |
Industry Comparison
This section compares HeraMED Limited's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $281,152,213
- Average return on equity (ROE) among peers: -82.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HeraMED Limited (1I4) | €2.77 Million | -86.78% | 0.62x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |